Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XOMA |
---|---|---|
10:51 ET | 300 | 23.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
XOMA Corp | 279.9M | -6.1x | --- |
Tenaya Therapeutics Inc | 285.8M | -2.3x | --- |
Inozyme Pharma Inc | 286.4M | -3.5x | --- |
Black Diamond Therapeutics Inc | 292.0M | -3.6x | --- |
Fractyl Health Inc | 295.0M | -3.5x | --- |
Century Therapeutics Inc | 244.5M | -1.5x | --- |
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $279.9M |
---|---|
Revenue (TTM) | $5.8M |
Shares Outstanding | 11.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-3.92 |
Book Value | $7.72 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | 48.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -665.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.